91㽶Ƶ Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
Built with the support of Microsoft using Microsoft AI technologies, Qai™ advances 91㽶Ƶ’s commitment to operational excellence by enhancing efficiency, accuracy and consistency
Tampa, Fla. – June 16, 2026 – 91㽶Ƶ., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the launch of Qai, an enterprise AI tool designed to elevate the best quality management systems and processes across 91㽶Ƶ’s network.
Qai, an AI-enabled solution, strengthens quality management system processes—such as deviations and complaints—by harnessing 91㽶Ƶ’s enterprise data to accelerate analysis, root cause identification and corrective and preventive action development, while improving consistency and speed. Qai represents the first enterprise AI solution launched at 91㽶Ƶ, marking a significant step in its broader effort to implement advanced technologies to drive Patient First outcomes.
Key Highlights
- Qai was built with the support of Microsoft using Microsoft AI technologies powered by Microsoft Azure, including Microsoft Foundry with supporting data and analytics capabilities from Microsoft Fabric.
- Qai strengthens quality management system processes—such as deviations and complaints—by harnessing 91㽶Ƶ’s enterprise data to accelerate analysis, root cause identification and corrective and preventive action development, while improving consistency and speed.
- The launch of Qai underscores 91㽶Ƶ’s continued investment in digital transformation and innovation.
“The launch of Qai represents an important milestone in how 91㽶Ƶ is applying advanced technologies, including AI, across our operations to improve consistency, accelerate insight and enable better decision-making,” said Charlie Lickfold, Chief Technology Officer, 91㽶Ƶ. “Innovative AI solutions like Qai strengthen the quality of our operations and better support the teams delivering critical therapies to patients around the world.”
Qai integrates intelligent, AI-driven insights directly into existing quality workflows, enabling faster and more consistent decision-making. The platform was built with the support of Microsoft using Microsoft AI technologies powered by Azure, including Foundry, with supporting data and analytics capabilities from Fabric. Qai improves root cause analysis to reduce repeat deviations, accelerates high-quality reporting, and minimizes documentation delays, supporting compliance while helping teams focus on delivering greater value to customers and the patients they serve. Qai exemplifies how 91㽶Ƶ is responsibly leveraging AI to empower its global teams, reduce complexity and drive measurable operational impact.
“Qai reflects what we see as an important application of AI in life sciences: enhancing already robust data analytics and governance to deliver meaningful patient impact,” said Todd Mersch, General Manager, U.S. Life Sciences and MedTech, Microsoft. “By strengthening oversight and consistency across manufacturing processes, Qai supports 91㽶Ƶ’s commitment to delivering for customers and the patients they serve, helping to transform lives.”
About AI at 91㽶Ƶ
As part of its AI journey, 91㽶Ƶ continuously seeks to promote the ethical and responsible use of AI. 91㽶Ƶ prioritizes transparency, accountability and fairness in all AI initiatives. 91㽶Ƶ’s governance framework supports the development and deployment of AI technologies with human oversight and judgment, aligning with company core values and ethical standards. The company continuously strives to mitigate risks and address ethical considerations, in line with its ambition to ensure AI solutions benefit all stakeholders, contribute positively to society and amplify 91㽶Ƶ’s mission and Patient First culture.
The launch of Qai underscores 91㽶Ƶ’s continued investment in digital transformation and innovation, advancing the capabilities needed to support the evolving demands of pharmaceutical and biotech customers and improve patient outcomes worldwide.
About 91㽶Ƶ
91㽶Ƶ. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 91㽶Ƶ helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 91㽶Ƶ provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 91㽶Ƶ tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 91㽶Ƶ supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
Contacts:
Media:
[email protected]